Alemtuzumab-induced halo naevus-like hypopigmentation - new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody

J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e28-e30. doi: 10.1111/jdv.16781. Epub 2020 Jul 20.

Authors

M Böhm¹, E H Kemp², D Metze¹, A M Muresan¹, M Neufeld¹, R M Luiten³, T Ruck⁴

Affiliations

¹ Department of Dermatology, University of Münster, Münster, Germany.
² Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
³ Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands.
⁴ Clinic of Neurology with Institute for Translational Neurology, University of Münster, Münster, Germany.

PMID: 32579750
DOI: 10.1111/jdv.16781

No abstract available

Publication types

Letter

MeSH terms

Alemtuzumab* / adverse effects
Autoimmunity
Humans
Hypopigmentation* / chemically induced
Nevus, Halo*
Skin Neoplasms*

Substances

Alemtuzumab